星期四, 6月 09, 2022

AG HEALEY REACHES SETTLEMENT WITH BOSTON HOUSING PROVIDER FOR FAILING TO ACCOMMODATE A YOUNG CHILD’S DISABILITY

 AG HEALEY REACHES SETTLEMENT WITH BOSTON HOUSING PROVIDER FOR FAILING TO ACCOMMODATE A YOUNG CHILD’S DISABILITY

Child with Asthma Exposed to Secondhand Smoke and Rodent Infestation; Case Is Part of AG’s Ongoing Efforts to Combat Housing Discrimination in Massachusetts, Including New Guidance for Landlords and Tenants 

            BOSTON – A property management company and its owner have agreed to pay $35,000 in restitution and implement no smoking policies in its Roxbury and Dorchester affordable housing units, to settle allegations that they unlawfully denied a tenant and their young disabled child the reasonable accommodations necessary to address secondhand smoke and a rodent infestation that posed a serious health risk to the child, Attorney General Maura Healey announced today.

To help educate landlords, tenants, and those in the real estate business about requirements to provide reasonable housing accommodations, the AG’s Office today issued new resource guidance with information on state and federal housing laws. The AG’s Office also issued guidance for tenants on what to do when conditions in a home negatively impact their health or the health of a family member. Both resources guides are available in English and Spanish.

“Housing providers cannot deny tenants their right to a safe and sanitary home,” said AG Healey. “My office is committed to enforcing nondiscrimination and other laws that protect vulnerable tenants from living in conditions that make them sick, and we will continue to educate landlords and tenants about their rights and obligations under the law when it comes to apartment conditions and accommodations.”

            According to the AG’s settlement with Peabody Properties, Inc., a large property management company, and the apartment’s owner, JPNDC Pitts MM LLC, the two companies violated the state's antidiscrimination and consumer protection laws by failing to make a reasonable accommodation for a young child with asthma, despite repeated requests from the child’s parent and medical team. JPNDC Pitts and Peabody Properties allegedly failed to adequately address secondhand smoke that was seeping into their apartment and failed to mitigate a serious rodent infestation in the building that was aggravating the child’s asthma. While the two companies initially provided air purifiers for the family’s unit at the time they moved in, the air purifiers did not abate the presence of secondhand smoke in the unit and the child suffered serious medical consequences as a result. Requests from the child’s parent and medical team to transfer to a non-smoking unit as further reasonable accommodation were ignored, and the child’s health worsened as a result.

Under the terms of the settlement, JPNDC Pitts and Peabody Properties have agreed to pay the family $35,000, to implement a no smoking policy across the entire JPNDC portfolio of affordable housing units – which includes more than 200 units in the Boston area – and develop a plan to ensure the policy is enforced. Peabody Properties has also agreed to assist the family in accessing waitlists for properties outside of the JPNDC Pitts property portfolio that are smoke-free.

            This case was referred to the AG’s Office from the Boston Fair Housing Commission, which found probable cause that the two companies failed to provide a reasonable accommodation.

AG Healey has been a leader in combatting housing discrimination in Massachusetts and has taken similar action involving discrimination against tenants with disabilities. In 2021, the AG’s Office reached a settlement with the Boston Housing Authority to resolve allegations that it denied a tenant and child with significant health issues access to suitable housing. During Fair Housing Month in April, the AG’s Office announced the resolution of four housing discrimination cases in which tenants were refused housing due to their receipt of public assistance. In the same month, AG Healey reached agreements with two companies as part of an ongoing investigation into the tenant screening and background check industry for potential discriminative algorithms being used to screen prospective tenants for housing. Additionally, in 2020, several South Shore real estate brokers resolved an investigation by the AG’s Office into allegations that they discriminated against prospective tenants based on receipt of public assistance.

 

The Massachusetts Attorney General’s Office is committed to enforcing the state’s antidiscrimination laws and encourages those who have concerns about housing discrimination to call the office’s Civil Rights Division at 617-963-2917 or to file a complaint online.

 

Today’s settlement matter was handled by Managing Attorney Amanda Hainsworth of AG Healey’s Civil Rights Division, with assistance from Ciara Tran of the AG’s Civil Investigations Division.

 

To view the AG’s reasonable accommodations resource guide for housing in English, click here. For Spanish, click here.  

 

To view the AG’s guidance on tenant rights related to apartment conditions in English, click here. For Spanish, click here.

U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)

 U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)

 
  • FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom treatment with Rozlytrek may be appropriate
  • This approval marks the first and only companion diagnostic indication for Rozlytrek, and another important milestone in tumour-agnostic approaches for people living with rare cancers
  • Roche is a leader in driving personalised healthcare around the world through validated diagnostic tools, genomic insights and a continued focus on drug development

Basel, 9 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (U.S. FDA) has approved Foundation Medicine’s FoundationOne®CDx as a companion diagnostic (CDx) for Roche’s Rozlytrek® (entrectinib). FoundationOne CDx is a comprehensive genomic profiling (CGP) pan-tumour tissue biopsy test that assesses an individual’s cancer to identify the unique molecular ‘fingerprint’ of the tumour. It is the first and only U.S. FDA-approved CDx to identify patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC), or patients with NTRK fusion-positive cancers, for whom treatment witRozlytrek may be appropriate.

“The ability to tailor cancer therapies based on specific genomic alterations using validated comprehensive genomic profiling (CGP) has transformed the traditional ‘one-size fits-all’ approach to cancer,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval marks a significant step forward in expanding treatment options and improving outcomes for patients, particularly those with rare tumours.”

Using CGP to identify the genomic alterations that are associated with driving an individual’s cancer can support physicians in making an informed treatment decision for the individual patient, potentially achieving better clinical outcomes.1

Rozlytrek is a targeted therapy approved to treat ROS1 fusion-positive metastatic NSCLC and a tumour-agnostic medicine for locally advanced or solid tumours that harbour NTRK fusions. ROS1 gene fusions account for 1-2% of NSCLC, the most common type of lung cancer that accounts for up to 85% of all diagnoses.2,3 NTRK gene fusions have been identified in a range of solid tumour types, and are present in up to 90% of some rare cancer types and less than 1% of other more common cancers, including lung and colorectal.4 

The approval is based on data from the phase I ALKA-372-001 (EudraCT 2012-000148-88), phase I STARTRK-1 (NCT02097810) and phase II STARKTRK-2 (NCT02568267) trials. As a condition of this approval, Foundation Medicine will conduct a post-approval study powered by the Flatiron Health-Foundation Medicine’s Clinico-Genomic Database (CGDB) to further demonstrate FoundationOne CDx’s ability to identify patients with ROS1 fusion-mutated NSCLC for whom treatment with Rozlytrek may be appropriate. The CGDB is a de-identified, HIPAA-compliant database that links outcomes data from Flatiron’s network of oncology clinics and genomic data from Foundation Medicine’s CGP assays. The database currently contains more than 100,000 linked genomic profiles , and is continually growing.

By combining tumour-agnostic drug development with data collection, high-quality diagnostics and the implementation of CGP, Roche is leading the realisation of personalised healthcare around the world, enabling physicians to develop tailored treatment strategies for each individual, and enable smarter, more efficient research and development to ensure no person is left behind.

星期三, 6月 08, 2022

波士頓市議會小砍吳弭市長預算案

            (Boston Orange 編譯) 波士頓市議會今年首度擁有市府預算增刪權,今 (8) 日立馬揮刀,從波士頓市長吳弭 (Michelle Wu)所遞交的399千萬元營運預算,砍掉1300萬元警察局開支。

吳弭市長可以接受或否決這一刪減行動,把預算案交回給波士頓市議會通過。如果波士頓市議會有三分之二議員同意,可以推翻波士頓市長的任何否決決定。

在今年以前,波士頓市議會只能同意或拒絕市長的總體預算提案,但是除非市長要求,不能搬動任何項目的提議預算金額。這情況已經讓波士頓市議會感到沮喪有很長一段時間了。

現在,只要不超過市長所提預算案的原始金額,也就是在某個項目上增加預算,就得在另一個項目上減少預算的情況下,波士頓市議會可以修訂預算了。

波士頓市為制定預算案,曾就部門預算,以及相關的動用資本項目,開過30場公聽會,其中包括2場是專為公眾參與而召開的會議,4場是工作會議。

波士頓市議會提出的修訂金額,在整體預算中只佔小如一滴水的份量,包括編列125千元聘請一名水前區計畫 (waterfront planning) 主任,增撥5萬元給英語作為第二語言課程,以及增撥15萬元資助同性戀 (LGBTQ)活動。

波士頓市議會提出的最大變動,是為青少年參與及就業項目增撥670萬元經費,在警察局的經費中刪減1300萬元,包括刪減1000萬元的警察加班費。

這些變動,將使波士頓市政府的新年度預算總額從399千萬元降至383千萬元。

吳弭提出的預算案是刪減警察預算1%,既讓要求大幅刪減的支持改革者們失望,也讓警察局的主要工會憤怒。

在其他事務上,波士頓市議會以103票,通過了波士頓公校的13億元預算。

波士頓市議會也授權同意36億元的樓宇翻修預算。這一部分還需再經過第二輪投票才能通過。

波士頓市議會議員Frank Baker表示,他很想知道幾星期後,吳弭市長把預算案交回給波士頓市議會時,會有多少他們提出的增刪要求被丟回到他們面前。

哈佛大學校長Lawrence Bacow 將於明夏卸任

哈佛大學校長鮑卡 (Lawrence Bacow)。檔案照片。
          (Boston Orange 編譯) 哈佛大學校長鮑卡 (Lawrence Bacow) (8) 日發信給該校師生,表示他將於明年6月卸任。

麻州的大學院校,最近有如浮現出走潮。麻省理工學院校長Rafael Reif,塔芙茨大學校長Tony Monaco,達特茅斯大學校長Philip Hanlon等人,都將於明年夏天卸任。

鮑卡 (Lawrence Bacow) 明年就72歲了。他是在美國政治動盪的川普政府時期,接任哈佛大學校長,接著帶領學校走過全球性的新冠病毒疫情。他說,要從像這樣的工作卸任,從來都沒有一個好時候,但現在對我來說似乎是對的事。他說他打算花更多時間和太太及許多孫子女相處。

鮑卡之前是塔芙茨大學校長,帶動哈佛大學成為一所更多元化,更向外看的機構,倡議平權行動,保護國際學生,加強和美國核心地帶的聯繫。在他任期中的下半段,幾乎所有優先要務都在挑戰所有大學的新冠病毒大流行淹沒中黯然失色。

鮑卡校長以溫暖,平易近人著稱。他歸功於學生,教授、職員及校友們幫助他領導哈佛度過風暴。

在新冠病毒大流行剛發生時,鮑卡動作很快,2020310日,在川普總統從白宮告訴全美這件事,以及全國籃球聯盟取消賽季之前2天,就已經下令哈佛學生在週末前離開校園。2星期之後,鮑卡和他太太Adele確診。那是他確診2刺中的第一次。

那年夏天,當美國移民及海關執法署提議,如果學生們的課業能夠在網上完成,就要逼使外籍學生們回到他們本國時,鮑卡和川普政府槓上了。鮑卡協助組織了大學聯盟,就此政策控告政府。移民局於是退縮。

維持學生群體的多元性是鮑卡所率領行政單位的首要考量。這也是他面對另一場風暴的原因。2014年的一場訴訟,稱哈佛大學的入學許可辦公室歧視亞裔,鮑卡就為該校把族裔列為入學許可決定因素,以有助於創造更多元學生群體的政策辯護。      

他說,每一個被錄取進哈佛大學的人,都有可給社區的獨特處,而他們要重新確認多元化的重要性,以及那對世界所代表的一切。2019年時,聯邦法院作出對哈佛有利的裁決。該案現由最高法院聆聽,預定明年會有結果。

在密西根出生的鮑卡是2018年接任哈佛大學校長的。他想要把哈佛打造成一個更加全國性的學校。去年他還主持該校出版詳述該校與奴隸關聯的報告,承諾該校將斥資一億元來推動各種計畫,聊以彌補。

白人及亞裔家長遞狀控告波士頓公校系統

             (Boston Orange 編譯) 由一群白人及亞裔家長組成的「學業優異家長聯盟 (Parent Coalition for Academic Excellence)67日向波士頓的聯邦上訴法庭遞狀,控告波士頓公校系統,希望逼使波士頓學區至少錄取5名他們的小孩進3所考試學校。

             家長聯盟辯稱,儘管他們的小孩成績夠好,去年基於區域號碼的臨時入學許可政策卻剝奪了小孩們在這些學校的學位。

             波士頓公校今年換了另一種入學許可政策,以社會經濟相似的區域為基礎來分配學位,同樣旨在增加考試學校的多元化。

             波士頓公校今日以訴訟案件正在進行中,表示不便置評。

             「學業優異家長聯盟」的Lisa Green表示,這宗訟案的主要爭議是尋求有效的禁止政府在做決策時,有任何的種族考慮。

             她說,這宗訴訟的真正目的是要推翻平權行動。

Governor Baker Nominates Attorney Claudine A. Cloutier as Associate Justice of the Superior Court and Clerk Magistrate Kimberly M. Foster as Associate Justice of the District Court

Governor Baker Nominates Attorney Claudine A. Cloutier as Associate Justice of the Superior Court and Clerk Magistrate Kimberly M. Foster as Associate Justice of the District Court

 

BOSTON – Today, Governor Baker nominated Attorney Claudine A. Cloutier as Associate Justice of the Superior Court and Clerk Magistrate Kimberly M. Foster as Associate Justice of the District Court.

 

“With the addition of these two nominees, the Massachusetts judiciary will receive two experienced candidates well-suited for their new roles,” said Governor Charlie Baker. “I am pleased to submit their nominations to the Governor’s Council for their advice and consent.”

 

“Attorney Cloutier and Clerk Magistrate Foster will bring diverse experiences to the judiciary if confirmed,” said Lt. Governor Karyn Polito. “We are proud to submit their nominations for consideration.”

 

The Superior Court, the trial court of general jurisdiction for Massachusetts, is committed to delivering high quality justice in a timely and fair manner in accordance with the rule of law. The Court's 82 justices sit in 20 courthouses in all 14 counties of the Commonwealth. The Superior Court has original jurisdiction in civil actions over $25,000 and in matters where equitable relief is sought. It also has original jurisdiction in actions including labor disputes where injunctive relief is sought, exclusive authority to convene medical malpractice tribunals, appellate jurisdiction over certain administrative proceedings, and may hold sittings for naturalization in any city or town. The Superior Court also has exclusive original jurisdiction of first-degree murder cases and original jurisdiction of all other crimes.

 

For more information about the Superior Court, please visit their homepage.

 

The District Court hears a wide range of criminal, civil, housing, juvenile, mental health, and other types of cases. District Court criminal jurisdiction extends to all felonies punishable by a sentence up to five years, and many other specific felonies with greater potential penalties; all misdemeanors; and all violations of city and town ordinances and by-laws. The District Court is located in 62 courts across the Commonwealth.

 

For more information about the District Court, visit their homepage.

 

Judicial nominations are subject to the advice and consent of the Governor’s Council. Applicants for judicial openings are reviewed by the Judicial Nominating Commission (JNC) and recommended to the governor. Governor Baker established the JNC in February 2015 pursuant to Executive Order 558, a non-partisan, non-political Commission composed of volunteers from a cross-section of the Commonwealth's diverse population to screen judicial applications. Twenty-one members were later appointed to the JNC in April 2015.

 

About Claudine A. Cloutier

 

Claudine A. Cloutier began her legal career in 1995 as a law clerk for the Massachusetts Superior Court. Then, in 1996, Attorney Cloutier joined Keches Law Group, P.C., first as an associate until 2006. Attorney Cloutier was then named Tort Department Manager, and later named partner in 2007, and currently still holds both roles. Attorney Cloutier is an active member of the community, serving as a trustee of the Fall River High School Alumni Scholarship Fund, a board member at the Foundation to Advance Catholic Education through the Diocese of Fall River and a member of the Suffolk University Law School Dean’s Cabinet. She received her bachelor’s degree from Yale University in 1992 and her Juris Doctorate from Suffolk University Law School in 1995.

 

About Kimberly M. Foster

 

Kimberly M. Foster began her career in the Massachusetts State Senate as a legislative aide for Senator Charlie E. Shannon in 1995. She then joined Hinckley, Allen and Snyder, LLP as a law clerk until 1999. Clerk Magistrate Foster then joined the City of Somerville’s Executive Office as an administrative aide to Mayor Dorothy A. Kelly Gay until her graduation from law school in 2001. Clerk Magistrate Foster then joined the Middlesex District Attorney’s Office and served as an Assistant District Attorney until 2004, before joining the Law Offices of Petruccelli and Foster and specializing in all aspects of criminal defense. In 2012, Clerk Magistrate Foster was appointed Chairperson of the Massachusetts Division of Insurance’s Board of Appeal, where she served until her 2019 appointment as Clerk Magistrate of the Somerville District Court. She is also an active member of the community, founding the Scott C. Foster Metabolic Research Fund and volunteering at the Cambridge Youth Dance Company and the Somerville Youth Soccer League. Clerk Magistrate Foster received her bachelor’s degree from Boston University in 1997 and her Juris Doctorate from Suffolk University Law School in 2001.

Massachusetts Rate of Opioid-Related Overdose Deaths Increased 8.8 Percent in 2021 Compared to 2020

 Massachusetts Rate of Opioid-Related Overdose Deaths Increased 8.8 Percent in 2021 Compared to 2020

 

Fentanyl continues as a major factor driving opioid-related deaths; rates among Black residents decreased

 

BOSTON (June 8, 2022) – The rate of opioid-related overdose deaths in Massachusetts increased by 8.8 percent in 2021 compared to 2020, according to preliminary data released today by the Massachusetts Department of Public Health (DPH). Drug overdose deaths in Massachusetts continue to trend lower than the nationwide figures. The rise in death rates reflects effects of the COVID-19 pandemic and an increasingly poisoned drug supply, primarily with the powerful synthetic opioid fentanyl.

 

There were 2,290 confirmed and estimated opioid-related overdose deaths in 2021, an estimated 185 more deaths than the prior year. Preliminary data from the first three months of 2022 show there were 551 confirmed and estimated opioid-related overdose deaths, a 4 percent decrease (an estimated 24 fewer deaths) than the same time last year.

 

Fentanyl remains a persistent factor in opioid-related overdose deaths in Massachusetts. Preliminary data show fentanyl was present at a rate of 93 percent where a toxicology report was available. The presence of fentanyl has increased about 1 percent per quarter since 2016, including in the pre-pandemic period from 2017 to 2019 when opioid-related overdose deaths in Massachusetts were on the decline.

 

The Baker-Polito Administration remains focused on the opioid epidemic and continues to invest millions of dollars to expand a wide range of harm reduction, substance use awareness, treatment intervention, and recovery services. The Administration’s Fiscal Year 2023 (FY23) budget proposal invests $543.8 million in total funding for a wide range of harm reduction, treatment, and recovery programs that support individuals struggling with substance addiction and programs that work to prevent substance addiction through education, prescription monitoring, and more. This builds on the work done by the Administration and the Legislature to nearly quadruple state funding to tackle the addiction crisis since 2015.

 

“Tackling the opioid epidemic remains an urgent priority for our Administration, which is why we have worked with the Legislature to quadruple funding for substance addiction treatment and prevention, but we know there is more work to do,” said Governor Charlie Baker. “Today’s report underscores the harmful impact that the COVID-19 pandemic and the scourge of fentanyl have had on those struggling with addiction, and we are committed to continuing our work with the Legislature and our colleagues in the addiction and recovery community to boost access to services and treatment.”

 

“Over the past several years, our Administration has focused on addressing the opioid epidemic and the ways in which it intersects with the challenges of the COVID-19 pandemic, by strengthening pathways to treatment and recovery services, and education and prevention tools,” said Lieutenant Governor Karyn Polito. “We will continue our comprehensive efforts while working with local public health officials to expand access to programs and services for those struggling with addiction.”

 

In 2021, the opioid-related overdose death rate in Massachusetts increased to 32.6 per 100,000 people as compared to 29.9 per 100,000 in the prior year. When comparing 2021 to 2020, the opioid-related overdose death rate among race and ethnic groups as a whole or by gender remained relatively stable, with Black non-Hispanic and Asian/Pacific Islander populations seeing small decreases and white non-Hispanic and Hispanic populations seeing small increases. One exception is American Indian/Alaska Native residents. The 2021 opioid-related overdose death rate for American Indian/Alaska Native residents was 118.6 per 100,000. While this population accounts for a small number of opioid-related overdose deaths (13 out of 2,234 confirmed deaths), American Indian/Alaska Native residents statistically had the highest opioid-related overdose death rate among all race/ethnicity groups last year.

 

There is clear evidence that the COVID-19 pandemic has had a profound impact on mental health and has led to increased substance use across the Commonwealth. A preliminary analysis of DPH’s COVID-19 Community Impact Survey, conducted to better understand the layered impacts of the pandemic, saw an increase in poor mental health and substance use since the pandemic began, especially among Black, Indigenous, people of color (BIPOC) and LGBTQ+ individuals.

 

“We continue to be relentless in our commitment to increase access to harm reduction services, low threshold housing and treatment,” said Health and Human Services Secretary Marylou Sudders. “By working to destigmatize addiction and meeting people where they’re at, including with an expanded array of harm reduction tools, we can reverse this negative trend.”

 

“We recognize the disproportionate burden of the opioid epidemic on historically marginalized communities, which have also borne the brunt of the ongoing pandemic and its destabilizing impacts on mental health and substance use,” said Public Health Commissioner Margret Cooke. “We continue to use a data-driven approach to identify new solutions and expand on existing programs at the community level to increase much-needed outreach, especially among communities of color.”

 

Since the start of the pandemic, the Administration has aggressively expanded existing substance use disorder treatment and overdose prevention initiatives, investing $120 million in prevention programs from fiscal years 2016 to 2022. DPH has distributed more than 143,000 naloxone kits since March 2020 to opioid treatment programs, community health centers, hospital emergency departments, and houses of correction. Exemptions for federal requirements for take-home doses of medication for opioid use disorder have allowed 34 percent of Massachusetts opioid treatment program patients to access this life-saving treatment as of January 2022, compared to the pre-pandemic average of 16 percent in December 2019 (with a high of 52 percent in June 2020).

 

DPH has also expanded harm reduction programs as part of its overall overdose prevention efforts, including low-threshold housing (transitional and permanent), post-overdose support teams for overdose survivors, and mobile addiction services to improve access to treatment for individuals.

 

After fentanyl, cocaine continues to be the next most prevalent drug among opioid-related overdose deaths, present in toxicology reports at a rate of 51 percent in 2021 – a 5 percent increase over 2020. Benzodiazepines were present in 31 percent of opioid-related fatal overdoses. The percentage of benzodiazepines has been declining since the last quarter of 2017.

 

Alcohol, a newly reported toxicology data point, was present in 29 percent of opioid-related overdose deaths. This was followed by prescription opioids in 13 percent, and heroin or likely heroin and amphetamines present in 10 percent. The rate of heroin or likely heroin present in opioid-related overdose deaths has been declining since 2014.

 

Among the other findings of the latest opioid report:

 

  • The confirmed opioid-related overdose death rate for all Black non-Hispanic residents fell from 37.5 to 35.1 per 100,000 between 2020 and 2021. The death rate for Asian/Pacific Islander non-Hispanic residents was relatively constant, going from 3.4 per 100,000 in 2020 to 3.3 per 100,000 in 2021.

 

  • Both white non-Hispanic and Hispanic residents experienced death rate increases, with white non-Hispanic rates rising from 33.8 to 35.9 per 100,000 and Hispanic rates from 35.4 to 38 per 100,000 between 2020 and 2021.

 

  • Males comprise 73 percent of all opioid-related overdose deaths occurring in 2021.
    • 50 percent of opioid-related deaths occurred in people who were between 25 and 44 years old, compared to 5 percent of all deaths
    • 41 percent were between 45 and 64 years old, compared to 17 percent of all deaths

 

  • In 2021, males ages 25-34 once again represented the greatest number, accounting for 21 percent of suspected opioid-related incidents with a known age and sex treated by Emergency Medical Services (EMS).

 

  • Naloxone was administered in 96 percent of acute opioid overdoses occurring in 2021. Of all opioid-related EMS incidents in 2021, 55.3 percent were categorized as acute opioid overdoses.

 

The following cities and towns experienced a notable decrease in opioid-related overdose deaths in 2021 compared with 2020. (Residence is the city/town where the decedent lived, and occurrence is where the death occurred.)

 

Towns Experiencing a Notable Decrease in Opioid-Related Overdose Deaths from 2020 to 2021 that Meet Criteria*

Town

Residence

Occurrence

Both

Framingham

X

Chicopee

X

Weymouth

X

 

 

The following cities and towns experienced a notable increase in opioid-related overdose deaths in 2021 compared with 2020.

 

Towns Experiencing a Notable Increase in Opioid-Related Overdose Deaths from 2020 to 2021 that Meet Criteria*

Town

Residence

Occurrence

Both

Attleboro

X

Burlington

X

Cambridge

X

Lowell

X

Lynn

X

New Bedford

X

Pittsfield

X

Taunton

X

Ware

X

Westfield

X

* Criteria are the difference in the number of deaths between 2020 and 2021 is 10 or more higher in absolute number and 20% or higher in percent change.